Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

SpringWorks Therapeutics logo

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

Advanced Chart

Key Stats

Today's Range
$46.99
$46.99
50-Day Range
$46.46
$46.99
52-Week Range
$28.21
$62.00
Volume
N/A
Average Volume
2.66 million shs
Market Capitalization
$3.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.57
Consensus Rating
Hold

Company Overview

SpringWorks Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

SWTX MarketRank™: 

SpringWorks Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 901st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SpringWorks Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    SpringWorks Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about SpringWorks Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SpringWorks Therapeutics has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SWTX.
  • Dividend Yield

    SpringWorks Therapeutics does not currently pay a dividend.

  • Dividend Growth

    SpringWorks Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for SWTX.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for SpringWorks Therapeutics this week, compared to 6 articles on an average week.
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SWTX Stock News Headlines

Your blueprint for crypto wealth
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
See More Headlines

SWTX Stock Analysis - Frequently Asked Questions

SpringWorks Therapeutics (NASDAQ:SWTX) issued its quarterly earnings data on Friday, May, 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.30. The company had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. SpringWorks Therapeutics had a negative net margin of 115.60% and a negative trailing twelve-month return on equity of 51.10%.

SpringWorks Therapeutics subsidiaries include these companies: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..

SpringWorks Therapeutics (SWTX) raised $126 million in an IPO on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Top institutional investors of SpringWorks Therapeutics include Alpine Associates Management Inc. (1.52%), KRYGER CAPITAL Ltd (1.02%), Syquant Capital Sas (0.33%) and Credit Industriel ET Commercial (0.32%). Insiders that own company stock include Orbimed Advisors Llc, Saqib Islam, Badreddin Edris, Daniel Lynch, Bhavesh Ashar, Daniel Pichl and Julie Hambleton.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/09/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SWTX
CIK
1773427
Fax
N/A
Employees
230
Year Founded
2017

Price Target and Rating

High Price Target
$68.00
Low Price Target
$47.00
Potential Upside/Downside
+11.9%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$258.13 million
Net Margins
-115.60%
Pretax Margin
-115.60%
Return on Equity
-51.10%
Return on Assets
-43.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.33
Quick Ratio
4.18

Sales & Book Value

Annual Sales
$191.59 million
Price / Sales
18.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.47 per share
Price / Book
7.26

Miscellaneous

Outstanding Shares
75,350,000
Free Float
69,449,000
Market Cap
$3.54 billion
Optionable
Optionable
Beta
0.68

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:SWTX) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners